Gensco Laboratories LLC d/b/a Gensco Pharma, a Florida-based company involved in specialty pharmaceuticals, announced on Tuesday that it has acquired the global rights and intellectual property for the first and only rizatriptan Oral Dissolvable Film (ODF), co-developed under the trade names RizaFilm in the US and both RizaFilm and RizaPort globally.

The company said that with this acquisition, it is advancing its strategic initiatives by bringing innovative migraine treatment solutions to patients worldwide. RizaFilm is currently approved by the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of migraine and associated nausea, photophobia and phonophobia. The EMA approval is from age 6 and upwards with the FDA approval from age 6-11 planned at launch.

With FDA and EMA approvals already secured, the company is ramping up manufacturing and actively preparing for a US launch of RizaFilm in Q4 2025. Concurrently, Gensco is working with existing and new licensing partners to expand market availability for RizaFilm and RizaPort internationally including China, India, the Middle East and the Americas.

With global licensing discussions underway and a global supply chain, Gensco anticipates strong adoption by both patients and prescribers.